<div id="readability-page-1"><p><span>Equillium (NASDAQ:EQ - Get Free Report)</span> was downgraded by Wall Street Zen from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report issued on Saturday.</p><ul><li>REITs Set for a 2026 Rebound? 7 Top Picks as Rate Cuts Approach</li></ul><p>Several other research analysts have also recently weighed in on the company. Stifel Nicolaus assumed coverage on Equillium in a research report on Wednesday. They set a &#34;buy&#34; rating and a $5.00 price objective on the stock. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Equillium in a research report on Monday, December 29th. One analyst  has rated the stock with a Buy rating, one  has issued  a Hold rating and one  has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of &#34;Hold&#34; and an average target price of $3.00.</p><p><b>View Our Latest Analysis on Equillium</b></p><h2>Equillium Stock Up 4.9%</h2><ul><li>Guidance, Not Earnings, Sends Equinix Stock Higher</li></ul><p>Shares of NASDAQ:EQ opened at $1.82 on Friday. Equillium has a 12-month low of $0.27 and a 12-month high of $2.35. The business has a 50 day moving average of $1.45 and a 200-day moving average of $1.37. The stock has a market cap of $110.82 million, a PE ratio of -2.94 and a beta of 1.87. </p><h2>Insider Activity at Equillium</h2><p>In other news, COO Christine Zedelmayer sold 185,937 shares of the business's stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $1.76, for a total value of $327,249.12. Following the completion of the transaction, the chief operating officer directly owned 191,444 shares in the company, valued at approximately $336,941.44. The trade was a 49.27% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders have sold 328,174 shares of company stock valued at $533,163. 31.60% of the stock is currently owned by insiders. </p><h2>Institutional Investors Weigh In On Equillium</h2><ul><li>The Cloud Computing ETF Every Growth Investor Should Consider</li></ul><p>Several hedge funds have recently modified their holdings of EQ. Janus Henderson Group PLC bought a new position in  Equillium in the fourth quarter valued at about $9,057,000.  ADAR1 Capital Management LLC bought a new stake in shares of  Equillium during the third quarter worth about $7,951,000.  Woodline Partners LP acquired a new position in shares of  Equillium in the third quarter valued at approximately $5,018,000.  Aberdeen Group plc raised its holdings in  Equillium by 523.6% in the 4th quarter. Aberdeen Group plc now owns 2,366,688 shares of the company's stock valued at $3,668,000 after buying an additional 1,987,162 shares during the last quarter.  Finally, Vanguard Group Inc. raised its holdings in  Equillium by 59.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,313,946 shares of the company's stock valued at $1,879,000 after buying an additional 489,855 shares during the last quarter. Institutional investors and hedge funds own  27.05% of the company's stock. </p><h2>About Equillium</h2> (Get Free Report)<p>Equillium, Inc <span>NASDAQ: EQ<span></span></span> is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company's lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium's pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.  </p><p>Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody's established safety profile in earlier clinical studies.</p><h2>See Also</h2><ul><li>Five stocks we like better than Equillium</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li><li>MAJOR BUY ALERT: Mar-a-Lago/Trump/Elon</li><li>The Biggest IPO Ever… Open to Everyday Folks</li><li>Silver records prices are great. Monthly income is better</li><li>Read this or regret it forever</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Equillium Right Now?</h2><p>Before you consider Equillium, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Equillium wasn't on the list.</p><p>While Equillium currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

LABD

SBIO

IBBQ

<p>Wall Street Zen downgraded Equillium (NASDAQ:EQ) from a "hold" to a "sell" rating in a recent report. The stock currently has a consensus rating of "Hold" with an average target price of $3.00. Other analysts have mixed ratings, with one buy, one hold, and one sell. Equillium's shares opened at $1.82, with a 12-month range of $0.27 to $2.35. Insider activity includes COO Christine Zedelmayer selling 185,937 shares. Institutional investors own 27.05% of the stock, with recent significant purchases from various hedge funds.</p>

Equillium (NASDAQ:EQ) Downgraded by Wall Street Zen to "Sell"